SLC5A2 and coronary artery disorder: Additionally, SGLT2 inhibitors were postulated to enhance the synthesis of erythropoietin, with the expectation that an increase in red cell mass might increase oxygen delivery to the myocardium, which could be important in those with underlying ischemic heart disease [8].